Avenue Therapeutics, Inc. Common Stock
ATXI
ATXI was delisted on the 18th of March, 2025.
34 hedge funds and large institutions have $28.1M invested in Avenue Therapeutics, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 10 increasing their positions, 1 reducing their positions, and 4 closing their positions.
900% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 1
375% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 4
79% more funds holding
Funds holding: 19 → 34 (+15)
60% more capital invested
Capital invested by funds: $17.6M → $28.1M (+$10.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.73M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.22M |
| 3 |
State Street
Boston,
Massachusetts
|
+$677K |
| 4 |
Renaissance Technologies
New York
|
+$575K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$474K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$631K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$181K |
| 3 |
Goldman Sachs
New York
|
-$138K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$45.1K |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$22K |
ATXI Hedge Fund Activity: Q2 2020 in Review
34 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Avenue Therapeutics, Inc. Common Stock (ATXI) for Q2 2020, worth a combined $28.1M — up 60% from $17.6M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new ATXI positions and 4 closed out — a net gain of 15 holders — while 10 added to existing stakes and 1 trimmed.
The largest buyer was BlackRock, adding an estimated $2.73M. The largest seller was Millennium Management, exiting entirely with an estimated $631K sold.
- 34 institutional investors held Avenue Therapeutics, Inc. Common Stock (ATXI) as of Q2 2020, up from 19 in Q1 2020.
- Funds reported $28.1M of Avenue Therapeutics, Inc. Common Stock stock for Q2 2020, up 60% quarter-over-quarter.
- 19 funds opened new Avenue Therapeutics, Inc. Common Stock positions in Q2 2020 and 4 closed out, a net change of +15 holders.
- The largest Avenue Therapeutics, Inc. Common Stock buyer in Q2 2020 was BlackRock, an estimated $2.73M added.
- The largest Avenue Therapeutics, Inc. Common Stock seller in Q2 2020 was Millennium Management, an estimated $631K sold.
Based on aggregated 13F filings for Q2 2020.